Insider · CIK 0001518735
Jerome J Dvonch
Files at SNOA (Sonoma Pharmaceuticals, Inc.). First filing -, latest -.
In brief
Jerome J Dvonch files SEC Form 4 as CFO at SNOA (Sonoma Pharmaceuticals, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jerome J Dvonch has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026 | SNOA Sonoma Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +10,000 | $0.00 | $0 | 44,391 | Jul 9, 2026 |
| Jan 2, 2026 | SNOA Sonoma Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +5,000 | $0.00 | $0 | 34,391 | Jan 2, 2026 |
| Jun 19, 2025 | SNOA Sonoma Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +13,500 | $0.00 | $0 | 25,515 | Jun 20, 2025 |
| Jan 2, 2025 | SNOA Sonoma Pharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +10,000 | $0.00 | $0 | 15,891 | Jan 3, 2025 |
| Dec 29, 2023 | SNOA Sonoma Pharmaceuticals, Inc. | AGrant or award Stock option (right to buy)derivative | +60,000 | - | - | 117,777 | Dec 29, 2023 |
Questions about Jerome J Dvonch
Answered from the filings on this page, as of the latest one.
Is Jerome J Dvonch buying or selling?
Jerome J Dvonch has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jerome J Dvonch's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jerome J Dvonch has 0.
Where does Jerome J Dvonch file Form 4?
Jerome J Dvonch has filed Form 4 at SNOA (Sonoma Pharmaceuticals, Inc.) as Interim CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.